Cipla shares in focus after receiving CDSCO nod to launch inhalation insulin

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for managing type 1 and type 2 diabetes. Clinical trials in India demonstrated its effectiveness in reducing HbA1c levels. Cipla aims to improve diabetes management accessibility with this innovative treatment.

Market to consolidate for another month, prioritise quality over momentum & value: Sunil Subramaniam

Market expert Sunil Subramaniam analyzes current market trends, citing low consumer spending, government underspending, and FII selling. He anticipates a market consolidation phase for another month, advising investors to prioritize quality stocks and remain patient. Subramaniam predicts increased government spending, improved earnings, and renewed FII interest by mid-January, driven by upcoming elections and budget expectations.

Sleeping giant HDFC Bank shares wakes up with Rs 3 lakh crore rally

HDFC Bank’s shares surged by Rs 3 lakh crore in six months, reclaiming its position as a top wealth creator. The bank’s post-merger balance sheet is stronger, outperforming rivals with a 19% increase in share value. Brokerages predict further growth, setting target prices as high as Rs 2,550, driven by strong FII interest and resilient asset quality.

Mark Mobius says US Justice Department had no business prosecuting Adani Group; has a Santa gift for investors

Veteran investor Mark Mobius expresses skepticism about the US Justice Department’s involvement in probing an Indian company, Adani Group. He emphasizes the need for concrete evidence and anticipates a decrease in such international prosecutions under the Trump administration. Mobius highlights Adani’s infrastructure expertise and sees value in Indian power and telecom stocks, driven by growth and technological advancements.